Hormonal
Specific gut microbiota strains (e.g., Lactobacillus, Bifidobacterium) and their metabolites (SCFAs, neurotransmitters) regulate the Hypothalamus-Pituitary-Adrenal (HPA) axis and stress response, with germ-free animals showing exaggerated stress hormone release that is reversed by microbial colonization.
Your gut bacteria talk to your brain and stress system. Studies show that without gut bacteria, stress responses are exaggerated. You can support your mental resilience and stress handling by consuming probiotics (like Lactobacillus and Bifidobacterium) and prebiotics. These microbes help regulate your stress hormones and produce neurotransmitters that calm the nervous system.
In GF mice, a mild restraint stress induced an exaggerated release of corticosterone and ACTH compared to the specific pathogen free (SPF) controls, thus elucidating a connection between the gut microbiota and HPA axis [46].
Why this rating
Based on murine models (germ-free mice); human data is observational or mechanistic (probiotic effects on cortisol) but less definitive for causality in stress response.
Source
Exercise-induced stress behavior, gut-microbiota-brain axis and diet: a systematic review for athletes
Allison Clark et al. · Journal of the International Society of Sports Nutrition · 2016
DOI 10.1186/s12970-016-0155-6
More from this paper
- Intense exercise (above 60% VO2max) causes gastrointestinal hyperpermeability ('leaky gut') and endotoxemia by reducing splanchnic blood flow and increasing stress hormones, which can be mitigated by microbiota-derived Short Chain Fatty Acids (SCFAs) that strengthen the intestinal barrier.Good
- Current elite athlete dietary guidelines, which recommend low fiber intake to minimize gastrointestinal distress, reduce microbiota diversity and functionality, thereby exacerbating exercise-induced stress, gut permeability, and mood disturbances.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →